Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma鈥檚 ambitious pipeline touches dozens of rare genetic diseases, which means each SEC document is dense with trial data, cash-runway tables and licensing terms. If you have ever typed 鈥淏ridgeBio Pharma SEC filings explained simply鈥� or hunted through a 200-page report for one orphan-drug update, you know how time-consuming it can be.
Stock Titan solves that problem. Our AI engine turns the company鈥檚 most complex disclosures into plain-language insights. Open a BridgeBio Pharma annual report 10-K simplified or drill into a BridgeBio Pharma quarterly earnings report 10-Q filing鈥攌ey figures, pipeline timelines and risk factors are highlighted automatically. Material news drops? A BridgeBio Pharma 8-K material events explained alert lands in your dashboard within seconds. Need trading color? We stream BridgeBio Pharma Form 4 insider transactions real-time so you never miss executive stock moves.
Here鈥檚 what you can uncover in seconds:
- Cash usage trends and dilution impact through BridgeBio Pharma earnings report filing analysis.
- Pipeline milestones linked to specific clinical programs, flagged across multiple forms.
- BridgeBio Pharma executive stock transactions Form 4 and broader insider trading Form 4 transactions for sentiment checks.
- BridgeBio Pharma proxy statement executive compensation details, including option grants and performance metrics.
Whether you鈥檙e understanding BridgeBio Pharma SEC documents with AI for the first time or monitoring seasoned positions, every filing type鈥�10-K, 10-Q, 8-K, S-1, SC 13D and more鈥攗pdates in real time from EDGAR. Spend less time scrolling and more time acting on the genetic-medicine data that moves the market.
BridgeBio Pharma director Charles J. Homcy executed pre-planned stock sales under a Rule 10b5-1 plan, selling a total of 300,000 shares of BBIO across transactions dated 08/08/2025 and 08/11/2025. The filings show sales of 191,662 shares at a weighted average price near $45.87, 58,338 shares at a weighted average near $46.64, and 50,000 shares at $48, leaving the reporting person with 916,674 shares following the final sale.
The disclosure notes the transactions were effected under a 10b5-1 plan adopted May 8, 2025, and the reporter remains a significant holder with well over nine hundred thousand shares. All sales are reported as direct holdings without derivative activity disclosed.
BridgeBio Pharma (BBIO) Form 4 filed by Maricel Apuli, Chief Accounting Officer, reports a sale on 08/07/2025 of 1,000 shares of common stock at $45.44 per share. After the transaction, Apuli directly beneficially owned 141,859 shares. The form was signed on 08/11/2025. No derivative transactions were reported.
BridgeBio Pharma CEO and director Kumar Neil reported the sale of common stock on August 7鈥�8, 2025. The Form 4 discloses total dispositions of 217,404 shares, and notes the transactions were effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025.
Footnotes disclose weighted average sale price ranges of approximately $44.31鈥�$47.20 per share across the transactions. The filing lists indirect beneficial ownership following the reported transactions, including holdings of 4,718,447 and 915,686 shares via two trusts, and is signed by an attorney-in-fact on August 11, 2025.
BridgeBio Pharma filed a Form 144 reporting a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,400,000. The filing shows 191,168,504 shares outstanding.
The 50,000 shares to be sold were acquired on 07/01/2019 as founders' shares from the issuer and paid for in cash. The filing also discloses three sales by Charles J Homcy on 08/08/2025 totaling 250,000 common shares with gross proceeds of $6,907,905, $2,302,295 and $2,302,220 (combined $11,512,420).
BridgeBio Pharma, Inc. (BBIO) filed a Form 144 disclosing a proposed sale of 250,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $11,512,420.00 and total shares outstanding reported as 191,168,504. The securities were acquired as founder shares on 07/01/2019 from the issuer and payment was recorded on that date. The filing reports no securities sold during the past three months. The notice includes the required representation about no undisclosed material adverse information. The document does not provide identifying filer contact details or a listed plan adoption date for any Rule 10b5-1 trading plan.
Form 144 summary for BridgeBio Pharma, Inc. (BBIO)
This Form 144 reports an insider sale on 08/05/2025: 17,167 common shares sold through Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) with an aggregate market value of $841,183.00. The filing lists 189,880,720 shares outstanding. The securities were acquired and paid for on 08/05/2025 via a stock option exercise from the issuer with cash payment. The filer reports "Nothing to Report" for securities sold in the past three months.
Note: Several filer and issuer contact fields in the form are blank in the provided text.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
